In TTNtv-positive patients, atrial fibrillation and ventricular arrhythmias are most prevalent in DCM (41% AF, 32% VA), but SCA rates are similar across G+/P-, NDLVC, and DCM.
Does the prevalence of atrial fibrillation, major ventricular arrhythmias, and sudden cardiac arrest/death differ across left ventricular morphofunctional phenotypes in patients with titin truncating variants?
In patients with titin truncating variants, the risk of atrial fibrillation and major ventricular arrhythmias correlates with left ventricular morphology and function, though arrhythmic events can still occur in the pre-cardiomyopathic phase.
Absolute Event Rate: 0% vs 0%
Abstract Background Loss-of-function variants in TTN-encoded titin are the most common genetic cause of dilated cardiomyopathy (DCM). In addition, titin truncating variants (TTNtvs) are over-represented in early-onset atrial fibrillation (AF) and unexplained sudden cardiac arrest/death (SCA/SCD) suggesting that in rare circumstances TTNtvs may cause arrhythmias in a pre-cardiomyopathic electrical phase. Purpose To compare the prevalence of AF, sustained ventricular arrhythmias (VAs) and SCA/SCD between TTNtv-positive patients with genotype-positive but phenotype-negative (G+/P-) disease, non-dilated left ventricular cardiomyopathy (NDLVC) and DCM. Methods Retrospective review of 1,229 patients in our Arrhythmogenic/Dilated Cardiomyopathy Registry was used to identify those with TTNtvs in high proportion spliced-in (90%) exons classified as pathogenic or likely pathogenic according to current American College of Medical Genetics and Genomics variant classification guidelines. Demographic, electrocardiographic, imaging and outcome data were extracted from the electronic record. After exclusion of those without satisfactory imaging data, each TTNtv-positive patient was classified as having G+/P- disease, NDLVC, or DCM according to the 2023 European Society of Cardiology Guidelines for the management of cardiomyopathies. The prevalence of AF, non-SCA major VA events (sustained VT and appropriate VT/VF-terminating ICD therapies), and SCA/SCD was then compared between the three left ventricular morphofunctional subgroups. Results Overall, 232 TTNtv-positive patients (mean age of 44 ± 17 years; 57% male) were included (average LVEF of 39 ± 17%; 32% with a history of AF; 23% with a history of non-SCA VA event and 6% with a history of SCA). Forty-nine (21%) were G+/P-, 45 (19%) had NDLVC, and 138 (59%) had DCM at the time of their most recent clinical evaluation. As expected, the prevalence of AF was higher in TTNtv-DCM patients when compared to both TTNtv-NDLVC 56/138 (41%) vs. 11/45 (24%); p=0.04 and G+/P- disease 56/138 (41%) vs. 5/49 (10%); p0.001. Similarly, the number of patients who experienced a non-SCA major VA event was higher in TTNtv-DCM than either TTNtv-NDLVC 44/138 (32%) vs. 6/45 (9%); p=0.01 or G+/P- disease 44/138 (31%) vs. 4/49 (8%); p0.001. Interestingly, no difference in the number of TTNtv-positive patients who experienced a SCA/SCD was observed across subgroups 2/49 (4%) for G+/P-; 2/45 (4%) for NDLVC; and 8/138 (6%) for DCM; p=ns for all comparisons. Conclusion In patients with TTNtv substrates who were evaluated at a quaternary medical center, the prevalence of AF and major VA events correlates with left ventricular morphology/function with the greatest risk observed in those with DCM. However, the prevalence of AF and major VA events, including SCA, in TTNtv-positive patients with G+/P- and NDLVC disease is not trivial and highlights the ability of TTNtvs to present in a pre-cardiomyopathic electrical phase.
Coderre et al. (Sat,) reported a other. In TTNtv-positive patients, atrial fibrillation and ventricular arrhythmias are most prevalent in DCM (41% AF, 32% VA), but SCA rates are similar across G+/P-, NDLVC, and DCM.